{
  "id": 6898148,
  "title": "Perioperative atezolizumab + chemotherapy more than doubles event-free survival in resectable stage II–IIIB NSCLC",
  "url": "https://urgent.news/2026/09/12/perioperative-atezolizumab-chemotherapy-more-than-doubles-event-free",
  "topic": "science",
  "section": "Science",
  "published": "2026-09-12T09:20:08.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-09-perioperative-atezolizumab-chemotherapy-event-free.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "Patients with resectable stage II–IIIB non-small cell lung cancer (NSCLC) treated with perioperative atezolizumab plus platinum-based chemotherapy experienced a median event-free survival of 62.8 months compared with 34.9 months for patients receiving chemotherapy alone, according to final results from the Phase III IMpower030 trial.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Medical Xpress",
        "title": "Local consolidative therapy does not improve survival after dual immunotherapy in metastatic NSCLC",
        "url": "https://urgent.news/2026/09/12/local-consolidative-therapy-does-not-improve-survival-after-dual",
        "published": "2026-09-12T09:20:06.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}